Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Nov
03
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
Current Public Knowledge Rates on Alcohol and Cancer Risks
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo